A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
NCT ID: NCT07275242
Last Updated: 2026-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
107 participants
INTERVENTIONAL
2025-12-23
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
NCT06737731
A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
NCT05154604
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
NCT06618651
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
NCT05114759
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
NCT06643754
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low-Dose Group
SHR-A1811 Subcutaneous Injection
SHR-A1811 subcutaneous injection.
SHR-A1811 for Injection
SHR-A1811 for injection.
Medium-Dose Group
SHR-A1811 Subcutaneous Injection
SHR-A1811 subcutaneous injection.
SHR-A1811 for Injection
SHR-A1811 for injection.
High-Dose Group
SHR-A1811 Subcutaneous Injection
SHR-A1811 subcutaneous injection.
SHR-A1811 for Injection
SHR-A1811 for injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SHR-A1811 Subcutaneous Injection
SHR-A1811 subcutaneous injection.
SHR-A1811 for Injection
SHR-A1811 for injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Solid Tumor confirmed by histology or cytology;
3. ECOG score is 0 or 1;
4. An expected survival of ≥ 12 weeks;
5. At least one measurable lesion according to RECIST v1.1 criteria;
6. Have adequate renal and hepatic function;
7. Patients voluntarily joined the study and signed informed consent.
Exclusion Criteria
2. Patients have major surgical procedures or radiotherapy / chemotherapy within 4 weeks before the first medication;
3. History of immunodeficiency;
4. Clinically significant cardiovascular diseases;
5. Known or suspected interstitial lung disease;
6. Known hereditary or acquired bleeding thrombotic tendency;
7. Active hepatitis and liver cirrhosis;
8. Known allergic history of the drug components of this protocol;
9. History of neurological or psychiatric disorders.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHR-A1811(sc)-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.